Why Sarepta Therapeutics Inc. Stock Soared By 17% in 2014
Sarepta Therapeutics stock has been whipsawed over the past year. Find out what's been the cause of its volatility and whether or not the stock can head higher.
Is It Time to Buy GlaxoSmithKline plc Stock?
GlaxoSmithKline's stock has had a rough year due to falling revenues. Can the stock rebound?
COPD Occurs Most Often in These 5 States
COPD affects more than 6% of the U.S. population and costs $50 billion in direct and indirect costs annually, but these five states have the highest occurrence rate in the country.